Patent · US Expired

Substituted oxazinoisoquinoline derivatives, pharmaceutical compositions containing them and process for preparing same

US5494909A · kind A · utility

0Cited by
1References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 20, 1994
Grant dateFeb 27, 1996
Priority date
Expiry dateJul 20, 2014

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/28
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

New compounds with the ability to inhibit calcium uptake in the brains of mammals are disclosed of the Formula (I) ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 to C.sub.4 alkyl, phenyl, or phenyl-C.sub.1 to C.sub.4 alkyl; PA1 one of R.sup.2 and R.sup.3 is C.sub.1 to C.sub.4 alkoxy and the other one is phenyl-C.sub.1 to C.sub.4 alkoxy optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus; and PA1 R.sup.4 is phenyl optionally substituted by C.sub.1 to C.sub.4 alkyl in the aromatic nucleus, or their solvates, individual optically active and geometric isomers, mixtures of such isomers, as well as pharmaceutically acceptable acid addition salts thereof. The compounds of the Formula (I) are capable of inhibiting calcium uptake to brain cells and have a protective effect on hypobaric hypoxia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.